Prevention of Brain Injury by the Nonbacteriolytic Antibiotic Daptomycin in Experimental Pneumococcal Meningitis

Antimicrobial Agents and Chemotherapy
2007.0

Abstract

Bacteriolytic antibiotics cause the release of bacterial components that augment the host inflammatory response, which in turn contributes to the pathophysiology of brain injury in bacterial meningitis. In the present study, antibiotic therapy with nonbacteriolytic daptomycin was compared with that of bacteriolytic ceftriaxone in experimental pneumococcal meningitis, and the treatments were evaluated for their effects on inflammation and brain injury. Eleven-day-old rats were injected intracisternally with 1.3 x 10(4) +/- 0.5 x 10(4) CFU of Streptococcus pneumoniae serotype 3 and randomized to therapy with ceftriaxone (100 mg/kg of body weight subcutaneously [s.c.]; n = 55) or daptomycin (50 mg/kg s.c.; n = 56) starting at 18 h after infection. The cerebrospinal fluid (CSF) was assessed for bacterial counts, matrix metalloproteinase-9 levels, and tumor necrosis factor alpha levels at different time intervals after infection. Cortical brain damage was evaluated at 40 h after infection. Daptomycin cleared the bacteria more efficiently from the CSF than ceftriaxone within 2 h after the initiation of therapy (log(10) 3.6 +/- 1.0 and log(10) 6.3 +/- 1.4 CFU/ml, respectively; P < 0.02); reduced the inflammatory host reaction, as assessed by the matrix metalloproteinase-9 concentration in CSF 40 h after infection (P < 0.005); and prevented the development of cortical injury (cortical injury present in 0/30 and 7/28 animals, respectively; P < 0.004). Compared to ceftriaxone, daptomycin cleared the bacteria from the CSF more rapidly and caused less CSF inflammation. This combined effect provides an explanation for the observation that daptomycin prevented the development of cortical brain injury in experimental pneumococcal meningitis. Further research is needed to investigate whether nonbacteriolytic antibiotic therapy with daptomycin represents an advantageous alternative over current bacteriolytic antibiotic therapies for the treatment of pneumococcal meningitis.

Knowledge Graph

Similar Paper

Prevention of Brain Injury by the Nonbacteriolytic Antibiotic Daptomycin in Experimental Pneumococcal Meningitis
Antimicrobial Agents and Chemotherapy 2007.0
Attenuation of Cerebrospinal Fluid Inflammation by the Nonbacteriolytic Antibiotic Daptomycin versus That by Ceftriaxone in Experimental Pneumococcal Meningitis
Antimicrobial Agents and Chemotherapy 2010.0
Daptomycin Produces an Enhanced Bactericidal Activity Compared to Ceftriaxone, Measured by [ <sup>3</sup> H]Choline Release in the Cerebrospinal Fluid, in Experimental Meningitis Due to a Penicillin-Resistant Pneumococcal Strain without Lysing Its Cell Wall
Antimicrobial Agents and Chemotherapy 2007.0
Efficacy Profiles of Daptomycin for Treatment of Invasive and Noninvasive Pulmonary Infections with Streptococcus pneumoniae
Antimicrobial Agents and Chemotherapy 2010.0
Rapid Bactericidal Activity of Daptomycin against Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Peritonitis in Mice as Measured with Bioluminescent Bacteria
Antimicrobial Agents and Chemotherapy 2007.0
Activity of Daptomycin against Listeria monocytogenes Isolates from Cerebrospinal Fluid
Antimicrobial Agents and Chemotherapy 2008.0
Bactericidal Action of Daptomycin against Stationary-Phase and Nondividing Staphylococcus aureus Cells
Antimicrobial Agents and Chemotherapy 2007.0
Daptomycin Exerts Bactericidal Activity without Lysis of Staphylococcus aureus
Antimicrobial Agents and Chemotherapy 2008.0
Efficacy of Daptomycin against Bacillus anthracis in a Murine Model of Anthrax Spore Inhalation
Antimicrobial Agents and Chemotherapy 2010.0
The action mechanism of daptomycin
Bioorganic &amp; Medicinal Chemistry 2016.0